Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance
Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance
批准号:
8934513
负责人:
Zihai Li
金额:
$22.38万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-01 至 2020-08-31
关键词:
AddressBindingBiochemistryBiogenesisBiologicalBiological MarkersBiologyBreast Cancer cell lineBreast CarcinomaCancer BiologyCell surfaceClientClipCollectionColonColon CarcinomaDataDegradation PathwayDevelopmentDiagnosticDiseaseDockingERBB2 geneElementsEndoplasmic ReticulumEnzyme-Linked Immunosorbent AssayFoundationsFutureGeneticHeat-Shock Proteins 90HumanImmuneImmune ToleranceImmune responseImmunohistochemistryIn VitroInflammationInsulin-Like Growth Factor IIIntegrin BindingIntegrinsInvestigationKnock-in MouseKnockout MiceLaboratoriesLeadLinkLungMalignant NeoplasmsMalignant neoplasm of liverMalignant neoplasm of lungMammary NeoplasmsMammary glandMembraneModelingMolecularMolecular ChaperonesMonoclonal AntibodiesMultiple MyelomaMusNeoplasm MetastasisNull LymphocytesOncogenicPathologyPathway interactionsPlayPrimary carcinoma of the liver cellsProcessPromoter RegionsPropertyProstateProteinsQuality ControlReagentRegulationResearch PersonnelRoleSurfaceSystemTetanus Helper PeptideTherapeuticTissue MicroarrayToll-like receptorsTransforming Growth Factor betaTransforming Growth FactorsTumor Tissuecancer therapycell growthcell typeclinically significantgenetic approachhuman TLR7 proteinin vivoinhibitor/antagonistlipoprotein receptor-related protein 6malignant breast neoplasmmalignant mouth neoplasmmalignant stomach neoplasmmigrationmouse modelnew therapeutic targetnoveloutcome forecastoverexpressionparalogous geneprotein degradationresponsetargeted cancer therapytherapeutic targettraffickingtumorigenesis
中文摘要
项目摘要
grp 94作为一种普遍存在于内质网中的HSP 90蛋白,对蛋白质的质量起着重要的作用
通过参与未折叠蛋白质反应和ER相关蛋白质反应来控制分泌途径。
蛋白质降解途径它在癌症中过度表达,水平越高,预后越差,
但表达水平和病理学之间的潜在关系尚不清楚。从历史上看,
已经在宿主对癌症的免疫应答的背景下研究了grp 94,但没有在
癌症生物学本身在过去的十年里,我们的实验室一直致力于确定
GRP 94基因的表达。使用cre-loxP系统,我们产生了条件性grp 94敲除(KO)
小鼠模型对各种细胞类型特异性grp 94缺失小鼠的功能分析发现,
GRP 94是控制细胞生长、迁移和分化的几个关键途径的专性伴侣蛋白,
包括整合素、Toll样受体(TLR)、Wnt共受体LRP 6和细胞表面TGFβ-对接,
GARP分子。因此,grp 94已经成为癌症治疗的重要战略目标。这个项目
将专注于grp 94-GARP-TGFβ轴的乳腺癌生物学。我们的首要假设是
grp 94是通过GARP调节细胞表面TGFβ表达的关键分子伴侣,
它的激活过程通过整合素。强有力的初步数据支持这一假设。我们已经获得了这两个在
体外和体内证据表明grp 94控制GARP以及整联蛋白的细胞表面表达。GARP是
整合素是将潜伏性TGFβ与细胞表面对接所需的,而整合素有助于潜伏性TGFβ活化。的
通过新的初步数据已经确定了grp 94-GARP-TGFβ轴在癌症中的癌症相关性
包括多种原发性人类癌症的肿瘤/组织微阵列的广泛免疫组织化学,
证实了癌症中GARP蛋白的异常表达与较差的存活率之间的相关性。
还观察了GARP过表达在促进乳腺癌和免疫耐受中的影响。
因此,我们准备研究grp 94-GARP-TGFβ轴的机制和生物学影响,
癌症生物学我们的第一个目标是将GARP作为一种新的grp 94客户蛋白,确定grp 94的作用,
在调节表面TGFβ生物合成和活化方面,并揭示了grp 94
调节GARP成熟和贩运。我们的第二个目标是确定grp 94的生物学意义-
使用几种新的小鼠模型在从头肿瘤发生中的GARP表达,
GARP基因表达。使用一组独特的GARP单克隆抗体,Aim 3将确定
乳腺癌中grp 94-GARP表达的临床意义及GARP是否可作为一种新的乳腺癌治疗方法的探讨
治疗靶点该项目将通过提供及时的答案来推进grp 94在癌症中的生物学领域,
许多悬而未决的问题,并通过铺平道路,最终解开监管电路的grp 94-
GARP-TGFβ通路对人类癌症的基本理解,预后和治疗。
英文摘要
PROJECT SUMMARY
As a ubiquitous HSP90 paralog in the endoplasmic reticulum, grp94 plays important roles in protein quality
control in the secretory pathway by participating in both the unfolded protein response and the ER-associated
protein degradation pathway. It is over-expressed in cancers, with higher levels conferring poorer prognosis,
but the underlying relationship between expression levels and pathology is unclear. Historically, the biology of
grp94 has been studied in the context of the host's immune response to cancer, but not in the context of
cancer biology per se. For the past decade, our laboratory has focused on determining the intrinsic properties
of grp94 via genetic approaches. Using the cre-loxP system, we generated a conditional grp94 knockout (KO)
mouse model. Functional analyses of various cell type-specific grp94 null mice have led to the discovery that
grp94 is an obligate chaperone controlling several key pathways for cell growth, migration and differentiation,
including integrins, Toll-like receptors (TLRs), Wnt co-receptor LRP6, and the cell surface TGFβ-docking
molecule GARP. Thus, grp94 has emerged as a strategically important target for cancer therapy. This project
will focus on the breast cancer biology of the grp94-GARP-TGFβ axis. Our overarching hypothesis is that
grp94 is a key molecular chaperone in regulating the expression of cell surface TGFβ through GARP as well as
its activation process via integrins. Strong preliminary data support this hypothesis. We have obtained both in
vitro and in vivo evidence that grp94 controls cell surface expression of GARP as well as integrins. GARP is
required for docking latent TGFβ to cell surface, whereas integrins contribute to latent TGFβ activation. The
cancer relevance of grp94-GARP-TGFβ axis in cancer has been established by new preliminary data
including extensive immunohistochemistry of tumor/tissue microarrays of multiple primary human cancers,
demonstrating the correlation between aberrant expression of GARP protein in cancers and worse survival.
The impact of GARP overexpression in promoting breast cancer and immune tolerance also was observed.
Thus, we are poised to study both the mechanism and the biological impact of the grp94-GARP-TGFβ axis in
cancer biology. Our first aim will establish GARP as a novel grp94 client protein, determine the roles of grp94
in regulating surface TGFβ biogenesis and activation, and uncover the detailed mechanism by which grp94
regulates GARP maturation and trafficking. Our second aim will pinpoint the biological significance of grp94-
GARP expression in de novo oncogenesis using several novel mouse models that allow precise control of
GARP expression genetically. Using a panel of unique GARP monoclonal antibodies, Aim 3 will determine the
clinical significance of grp94-GARP expression in breast cancer and address if GARP can serve as a novel
therapeutic target. This project will advance the field of grp94 biology in cancer by providing timely answers to
many outstanding questions and by paving the way to eventually unlock the regulatory circuit of the grp94-
GARP-TGFβ pathway for fundamental understanding, prognosis and treatment of human cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sexual Dimorphism in T Cell Exhaustion and Bladder Cancer
-
批准号:10629078
-
项目类别:
-
资助金额:$53.14万
-
财政年份:2023
-
负责人:Zihai Li
-
依托单位:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy Supplement
-
批准号:10818173
-
项目类别:
-
资助金额:$7.21万
-
财政年份:2021
-
负责人:Zihai Li
-
依托单位:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
-
批准号:10474548
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2021
-
负责人:Zihai Li
-
依托单位:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
-
批准号:10689068
-
项目类别:
-
资助金额:$53.79万
-
财政年份:2021
-
负责人:Zihai Li
-
依托单位:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
-
批准号:10275810
-
项目类别:
-
资助金额:$56.92万
-
财政年份:2021
-
负责人:Zihai Li
-
依托单位:
Integration of inflammation and cancer by molecular chaperone
-
批准号:10056559
-
项目类别:
-
资助金额:$16.12万
-
财政年份:2017
-
负责人:Zihai Li
-
依托单位:
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
-
批准号:9321008
-
项目类别:
-
资助金额:$133.53万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease
-
批准号:9026108
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
-
批准号:8934510
-
项目类别:
-
资助金额:$133.75万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
-
批准号:9770790
-
项目类别:
-
资助金额:$135.49万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Thrombocytes in Cancer Immunity
-
批准号:9235264
-
项目类别:
-
资助金额:$38.72万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
-
批准号:9135256
-
项目类别:
-
资助金额:$138.52万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease
-
批准号:9190367
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Thrombocytes in Cancer Immunity
-
批准号:10047658
-
项目类别:
-
资助金额:$22.51万
-
财政年份:2015
-
负责人:Zihai Li
-
依托单位:
Novel Chaperone Mechanism for Platelet Disorder
-
批准号:7934003
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Zihai Li
-
依托单位:
Molecular chaperones and immune tolerance
-
批准号:9440331
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2009
-
负责人:Zihai Li
-
依托单位:
gp96, TLR and immunologic tolerance
-
批准号:8091738
-
项目类别:
-
资助金额:$36.51万
-
财政年份:2009
-
负责人:Zihai Li
-
依托单位:
Molecular chaperones and immune tolerance
-
批准号:9310818
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2009
-
负责人:Zihai Li
-
依托单位:
gp96, TLR and immunologic tolerance
-
批准号:8029526
-
项目类别:
-
资助金额:$36.14万
-
财政年份:2009
-
负责人:Zihai Li
-
依托单位:
Novel Chaperone Mechanism for Platelet Disorder
-
批准号:7832482
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Zihai Li
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: